Related Experiment Video
Updated: Feb 4, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Tat-HA-NR2B9c attenuate oxaliplatin-induced neuropathic pain
Hai-Hui Zhou1, Li Zhang2, Hai-Xia Zhang1
1Division of Clinical Pharmacy, Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, China.
Abstract:
Oxaliplatin is a commonly used chemotherapy drug, which can produce acute and chronic peripheral neurotoxicity. Currently, there is no good therapeutic drug in clinic. Excessive stimulation of N-methyl-d-aspartate receptors (NMDARs) is crucial for the transmission of pain signals. However, directly inhibiting NMDARs can cause severe side effects because they have key physiological functions in the Central nervous system (CNS). Several years ago, we prepared a polypeptide Tat-HA-NR2B9c which can disturb NMDARs-postsynaptic density protein-95 (PSD-95) interaction. In this study, we studied whether Tat-HA-NR2B9c could be an effective treatment for oxaliplatin-induced neuropathic pain. To conform it, a rat model of oxaliplatin-induced neuropathic was established, and analgesic effect of Tat-HA-NR2B9c was studied. Here, we show that oxaliplatin induces the interaction of NMDARs with PSD-95. Uncoupling the complex by Tat-HA-NR2B9c has potent analgesic effect in oxaliplatin-induced cold hyperalgesia and mechanical allodynia without suppressing general behavioral. Tat-HA-NR2B9c neither inhibits NMDARs function nor impacts antitumor activity of oxaliplatin. Thus, this new drug may serve as a treatment for oxaliplatin-induced neuropathic pain, perhaps without major side effects.
Insights
A novel polypeptide, Tat-HA-NR2B9c, effectively treats chemotherapy-induced neuropathic pain by disrupting specific receptor interactions. This potential therapy offers pain relief without significant side effects or impacting cancer treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Oxaliplatin chemotherapy can cause debilitating neuropathic pain.
- Current treatments for oxaliplatin-induced neuropathic pain are limited.
- N-methyl-d-aspartate receptors (NMDARs) are involved in pain signaling but direct inhibition causes side effects.
Purpose of the Study:
- To investigate the efficacy of Tat-HA-NR2B9c in treating oxaliplatin-induced neuropathic pain.
- To determine if Tat-HA-NR2B9c can disrupt the NMDARs-PSD-95 interaction.
- To assess the safety and specificity of Tat-HA-NR2B9c.
Main Methods:
- Established a rat model of oxaliplatin-induced neuropathic pain.
- Administered Tat-HA-NR2B9c to assess its analgesic effects.
- Evaluated effects on NMDARs-PSD-95 interaction, pain behaviors, and general activity.
Main Results:
- Oxaliplatin treatment increased the interaction between NMDARs and PSD-95.
- Tat-HA-NR2B9c significantly reduced cold hyperalgesia and mechanical allodynia.
- The treatment did not impair general behaviors or the antitumor activity of oxaliplatin.
Conclusions:
- Tat-HA-NR2B9c effectively alleviates oxaliplatin-induced neuropathic pain.
- Disrupting the NMDARs-PSD-95 complex offers a targeted pain management strategy.
- Tat-HA-NR2B9c shows promise as a safe and effective therapeutic agent for chemotherapy-induced neuropathic pain.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Pain
Analgesia and Pain Management
Attenuated Total Reflectance (ATR) Infrared Spectroscopy: Overview
The ATR process begins by directing a beam...
Primary Motives: Sleep, Sex, and Pain Avoidance
Sleep is a fundamental physiological drive that fosters a state of restfulness crucial for several bodily functions. It facilitates body restoration, the process by which the body repairs, rejuvenates, and maintains itself during sleep, including memory...
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...

